UK approves J&J's oral psoriasis pill

By Reuters News

Oct 23 (Reuters) - Britain's medicines regulator on Friday approved Johnson & Johnson's JNJ.N daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy or painful patches.


Here are some details:

  • The Medicines and Healthcare products Regulatory Agency (MHRA) approved the oral drug Icotyde for people aged 12 and older who weigh at least 40 kg

  • The approval was based on four late-stage trials in 2,500 people with the disease, including 72 teenagers aged 12 to under 18

  • In all four studies, patients who took the drug saw better results after 16 weeks than those given a placebo, the regulator said

  • Icotyde was approved in the US earlier this year for the same condition — its first approved indication

  • The drug is made in collaboration with Protagonist Therapeutics PTGX.O

  • J&J is also studying the ⁠drug, chemically ​known as icotrokinra, for ulcerative colitis, psoriatic arthritis ​and Crohn's disease

  • The company expects the treatment to bring in $5 billion in peak sales across multiple indications

  • The drug competes with established psoriasis treatments such as Bristol Myers Squibb's BMY.N Sotyktu and AbbVie's blockbuster ABBV.N Skyrizi

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.